Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NBRV | Ordinary Shares | Award | $0 | +17.5K | +70.3% | $0.00 | 42.4K | Jul 28, 2021 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NBRV | Share Options | Award | $0 | +35K | $0.00 | 35K | Jul 28, 2021 | Ordinary Shares | 35K | $1.08 | Direct | F3, F4 |
Id | Content |
---|---|
F1 | The reported transaction involved the reporting person's receipt of a grant of 17,500 restricted stock units. The total reported in Column 5 includes the 17,500 newly awarded restricted stock units. |
F2 | The number of ordinary shares reported on this Form 4 reflects a 1-for-10 reverse stock split effected on December 3, 2020. |
F3 | The option was granted on July 28, 2021. |
F4 | One hundred percent (100%) of the option will vest on July 31, 2022, subject to the reporting person's continued service on the board of directors of Nabriva Therapeutics plc. |